Vaxart (VXRT) to Release Earnings on Thursday

Vaxart (OTCMKTS:VXRT) is anticipated to release its Q4 2025 resultson Thursday, March 12th. Analysts expect Vaxart to post earnings of ($0.08) per share and revenue of $35.95 million for the quarter. Investors are encouraged to explore the company’s upcoming Q4 2025 earning overview page for the latest details on the call scheduled for Thursday, March 12, 2026 at 4:30 PM ET.

Vaxart Trading Up 2.4%

OTCMKTS:VXRT opened at $0.74 on Friday. Vaxart has a 12 month low of $0.26 and a 12 month high of $0.84. The stock has a market capitalization of $177.68 million, a price-to-earnings ratio of -3.21 and a beta of 1.17. The firm has a fifty day simple moving average of $0.60 and a two-hundred day simple moving average of $0.45.

Hedge Funds Weigh In On Vaxart

Several large investors have recently added to or reduced their stakes in the business. Invesco Ltd. lifted its holdings in shares of Vaxart by 93.1% in the first quarter. Invesco Ltd. now owns 146,366 shares of the biotechnology company’s stock valued at $60,000 after purchasing an additional 70,568 shares in the last quarter. Jones Financial Companies Lllp grew its holdings in Vaxart by 276,364.7% during the first quarter. Jones Financial Companies Lllp now owns 478,284 shares of the biotechnology company’s stock worth $196,000 after buying an additional 478,111 shares in the last quarter. Goldman Sachs Group Inc. bought a new stake in Vaxart during the first quarter worth $31,000. Creative Planning purchased a new stake in Vaxart in the 2nd quarter valued at $33,000. Finally, Marshall Wace LLP purchased a new stake in Vaxart in the 2nd quarter valued at $794,000. Institutional investors own 18.05% of the company’s stock.

Analyst Ratings Changes

Separately, Wall Street Zen raised Vaxart to a “buy” rating in a research report on Friday, January 23rd. One investment analyst has rated the stock with a Buy rating, According to data from MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus price target of $2.00.

About Vaxart

Vaxart, Inc is a clinical-stage biotechnology company pioneering the development of oral recombinant vaccines administered in tablet form. Leveraging a proprietary, room-temperature-stable platform, the company aims to simplify vaccine delivery while eliciting both systemic and mucosal immune responses. Its technology is based on the replication-defective adenovirus vector system, which encodes target antigens designed to protect against a range of infectious diseases without the need for injections or cold-chain logistics.

The company’s pipeline includes multiple vaccine candidates in various stages of development.